J. LeLorier

S. Rinfret, A. Matteau, M. Dorais, 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Effectiveness of a change in reperfusion strategy to primary percutaneous coronary intervention in a nonselected population.

S. Rinfret, A. Matteau, M. Dorais, 2009, The Canadian journal of cardiology.

A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention

J. Tardif, M. Dubé, D. Mitchell, 2018, Molecular Diagnosis & Therapy.

Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis.

D. Mitchell, J. LeLorier, V. Fradet, 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidine (TZDs).

M. Dorais, J. LeLorier, 2008, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

Drug Utilization Review of Cholinesterase Inhibitors in Quebec

M. Dorais, C. Charbonneau, J. LeLorier, 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Treatment Persistence with Leukotriene Receptor Antagonists and Inhaled Corticosteroids

I. Chabot, L. Blais, M. Dorais, 2005, The Journal of asthma : official journal of the Association for the Care of Asthma.

Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.

L. Joseph, E. Rahme, S. Kong, 2001, British journal of clinical pharmacology.

Predictors of long-term persistence on statins in a subsidized clinical population.

J. LeLorier, V. S. Catalan, Vanessa S. Catalan, 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin

D. Mitchell, J. LeLorier, J. Guertin, 2016, Molecular Diagnosis & Therapy.

The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients

H. Cardinal, M. Dorais, F. Madoré, 2017, Clinical kidney journal.

The concept of the ‘percent wasted patients’ in preventive health strategies

H. Cardinal, M. Dorais, J. LeLorier, 2006, Pharmacoepidemiology and drug safety.

Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPD

J. LeLorier, A. Monfared, 2006, Pharmacoepidemiology and drug safety.

Bringing epidemiology into drug utilisation research

J. Avorn, J. Hallas, J. LeLorier, 2003, Pharmacoepidemiology and drug safety.

Persistence of use of lipid-lowering medications: a cross-national study.

J. Avorn, H. Mogun, M. Monane, 1998, JAMA.

Risk of spontaneous intracranial hemorrhage in HIV-infected individuals: a population-based cohort study.

C. Tremblay, J. LeLorier, J. Baril, 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Impact of a Cost‐Sharing Drug Insurance Plan on Drug Utilization Among Older People

E. Rahme, L. Blais, J. LeLorier, 2001, Journal of the American Geriatrics Society.

Patterns of amlodipine and felodipine use in an elderly Quebec population.

J. LeLorier, O. Sheehy, 2000, The Canadian journal of cardiology.

A willingness-to-pay assessment of parents’ preference for shorter duration treatment of acute otitis media in children

J. LeLorier, D. Chenevier, 2012, PharmacoEconomics.

Impact of Regulatory Guidances and Drug Regulation on Risk Minimization Interventions in Drug Safety

C. Craig, Y. Moride, J. LeLorier, 2012, Drug Safety.

Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea

J. LeLorier, A. K. Kamdeu Fansi, Jason Robert Guertin, 2012, Journal of medical economics.

Drug utilization review of celecoxib in Ontario.

J. LeLorier, F. Lavoie, C. Fitzsimon, 2003, Rheumatology.

Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

R. Diaz, J. Tardif, D. Waters, 2020, European heart journal. Quality of care & clinical outcomes.

Usefulness of probucol in treating primary hypercholesterolemia.

J. LeLorier, J. Davignon, M. Enjalbert, 1980, Canadian Medical Association journal.

Uptake of and response to norepinephrine by certain tissues of hypertensive rats.

J. LeLorier, J. Hedtke, F. E. Shideman, 1976, The American journal of physiology.

Pharmacoepidemiology and Pharmaceutical Reimbursement Policy

M. Levine, J. LeLorier, 2012 .

Use of combination therapy in asthma: are they prescribed according to guidelines.

L. Blais, J. LeLorier, A. Forget, 2007, Respiratory medicine.

Treatment of dyslipidemia: we don't know all we think we know.

J. LeLorier, 2006, The Canadian journal of cardiology.

Hypotension and Arteriovenous Shunting: Effects of Intravenous Infusion of Nitroprusside, Nitroglycerin and Phentolamine

J. LeLorier, L. Dumont, C. Chartrand, 1984, Angiology.

A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.

J. Tardif, M. Dubé, D. Mitchell, 2016, Pharmacogenomics.

Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy

L. Blais, J. Saint‐Hilaire, J. LeLorier, 2012, PharmacoEconomics.

Oral anticoagulants and the risk of osteoporotic fractures among elderly

M. Dorais, J. LeLorier, A. Castilloux, 2004, Pharmacoepidemiology and drug safety.

Long-term Mortality After Acute Kidney Injury in the Pediatric ICU.

V. Phan, M. Dorais, J. Lacroix, 2018, Hospital pediatrics.

Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis

E. Rahme, E. Latimer, A. Holbrook, 2022, JAAD international.

Inhaled corticosteroids and the risk of diabetes among the elderly.

N. Dendukuri, L. Blais, J. LeLorier, 2002, British journal of clinical pharmacology.

Association between the burden of disease and research funding by the Medical Research Council of Canada and the National Institutes of Health. A cross-sectional study.

M. Lamarre-Cliche, J. LeLorier, A. Castilloux, 2001, Clinical and investigative medicine. Medecine clinique et experimentale.

Association of inhaled corticosteroid use with cataract extraction in elderly patients.

S. Suissa, E. Garbe, J. LeLorier, 1998, JAMA.

Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).

L. Blais, J. LeLorier, A. Castilloux, 2005, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

The effect of listing ciprofloxacin in provincial formularies on hospitalizations for bronchitis and pyelonephritis

F. Derderian, J. LeLorier, 1998 .

Drug Reimbursement Policies in Canada—Need for Improved Access to Critical Therapies

J. Cox, A. Bell, J. LeLorier, 2008, The Annals of pharmacotherapy.

Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

Robert W. Platt, A. Levy, L. Lix, 2022, BMC Endocrine Disorders.

Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care.

M. Levine, K. Gaebel, J. LeLorier, 2007, Clinical and investigative medicine. Medecine clinique et experimentale.

The value of lowering blood pressure.

J. LeLorier, 2006, The Canadian journal of cardiology.

Potentiation of lidocaine toxicity by pentobarbital in the dog.

M. Caron, J. LeLorier, 1979, Toxicology and applied pharmacology.

Pharmacologically pertinent period of effect (PPPE)

J. LeLorier, M. Suissa, 2019, Pharmacoepidemiology and drug safety.

Insert art title here

J. LeLorier, L. Bjerre, 2002 .

Effect of norepinephrine on intramyocardial distribution of blood flow in normal and ischemic myocardium.

J. LeLorier, L. Dumont, 1977, Canadian journal of physiology and pharmacology.

Management of new symptoms of dyspepsia in the elderly in Quebec.

J. LeLorier, A. Castilloux, V. Page, 1997, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.

E. Burgess, I. Lange, J. LeLorier, 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Intravenous infusion of nitroglycerin: effects upon cardiovascular dynamics and regional blood flow distribution in conscious dogs.

J. LeLorier, L. Dumont, C. Chartrand, 1982, Canadian journal of physiology and pharmacology.

Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma.

J. Boivin, S. Suissa, E. Garbe, 1997, JAMA.

Depression, anxiety and adjustment disorder among patients with psoriasis receiving systemic agents: A retrospective cohort study in Quebec, Canada

E. Rahme, A. Holbrook, M. Brouillette, 2022, JEADV Clinical Practice.

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer

L. Blais, J. LeLorier, A. Desgagné, 2000 .

A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue.

H. Cardinal, M. Dorais, J. LeLorier, 2004, The Canadian journal of cardiology.

Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics

J. LeLorier, P. Huet, Jacques Lelorier, 1980, Clinical pharmacology and therapeutics.

Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application

R. Goyer, P. du Souich, J. LeLorier, 1983, Clinical pharmacology and therapeutics.

Comparison of efficacy and cost among lipid-lowering agents in patients with primary hypercholesterolemia.

F. Derderian, J. LeLorier, A. Lacour, 1998, The Canadian journal of cardiology.

Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario

J. LeLorier, G. Zhanel, A. Iliza, 2017, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Statins and cancer risk.

H. Behlouli, L. Pilote, J. LeLorier, 2008, The American journal of medicine.

Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population‐based study

J. Collet, C. Quach, J. LeLorier, 2005, Pharmacoepidemiology and drug safety.

Differences in persistence among different weekly oral bisphosphonate medications

J. LeLorier, O. Sheehy, M. Barbeau, 2009, Osteoporosis International.

Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures

J. LeLorier, O. Sheehy, M. Barbeau, 2009, Osteoporosis International.

Cost effectiveness of ‘on demand’ HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada

C. Tremblay, J. LeLorier, Madeleine Durand, 2015, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

The science of health technology assessment--clinical effectiveness of therapeutic interventions.

J. LeLorier, 2001, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

Effect of water deprivation and rehydration on gentamicin disposition in the rat.

P. du Souich, J. LeLorier, L. Dumont, 1981, The Journal of pharmacology and experimental therapeutics.

Autoinhibition in rabbit aortic strips after epinephrine.

J. LeLorier, E. Hong, E. Pardo, 1967, The Journal of pharmacology and experimental therapeutics.

High-pressure liquid chromatographic determination of lidocaine and its active deethylated metabolites.

J. LeLorier, A. Roussin, G. Caillé, 1980, Journal of pharmaceutical sciences.

Effect of the duration of infusion on the disposition of lidocaine in dogs.

J. LeLorier, G. Caillé, R. Moisan, 1977, The Journal of pharmacology and experimental therapeutics.

GLC determination of lidocaine in human plasma.

Y. Latour, J. LeLorier, G. Caillé, 1977, Journal of pharmaceutical sciences.

The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.

I. Chabot, M. Blackstein, J. LeLorier, 2008, European journal of cancer.

Lidocaine and pentobarbital: a potentially lethal drug-drug interaction.

J. LeLorier, 1978, Toxicology and applied pharmacology.

A Cost-Effectiveness Analysis of Biomarkers for Risk Prediction in Atrial Fibrillation

J. Tardif, J. LeLorier, D. Roy, 2023, Molecular Diagnosis & Therapy.

Osteoporosis among patients with type 1 and type 2 diabetes.

E. Rahme, J. LeLorier, A. Räkel, 2008, Diabetes & metabolism.

Association Between HIV Infection, Antiretroviral Therapy, and Risk of Acute Myocardial Infarction: A Cohort and Nested Case–Control Study Using Québec's Public Health Insurance Database

C. Tremblay, J. LeLorier, J. Baril, 2011, Journal of acquired immune deficiency syndromes.

Transplacental treatment of tachycardia-induced fetal heart failure with verapamil and amiodarone: a case report.

R. Gauthier, J. LeLorier, A. Grignon, 1985, American journal of obstetrics and gynecology.

Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.

J. LeLorier, N. Rawson, 2007, The Canadian journal of cardiology.

Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.

E. Rahme, S. Kong, L. Joseph, 2000, Arthritis and rheumatism.

Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study.

G. Koren, L. Blais, J. LeLorier, 2008, The Journal of clinical psychiatry.

Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids

J. Boivin, S. Suissa, E. Garbe, 1997, The Lancet.

Original article Savingsfrom theuseofaprobiotic formula inthe prophylaxis of antibiotic-associated diarrhea

J. LeLorier, J. Guertin, Alvine Adrienne, 2012 .

Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database.

M. Dorais, J. LeLorier, B. Ambegaonkar, 2010, The Canadian journal of cardiology.

J. Brophy, E. Rahme, P. Théroux, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Cost Effectiveness of the Sirolimus-Eluting Stent in High-Risk Patients in Canada

D. Cohen, S. Rinfret, E. Schampaert, 2006, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

J. LeLorier, J. Paradis, 2004, The New England journal of medicine.

Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk

D. Mitchell, J. LeLorier, J. Guertin, 2018, Molecular Diagnosis & Therapy.

Shanghai trial of nifedipine in the elderly (STONE).

P. Hamet, J. Zhu, P. Ghadirian, 1996, Journal of hypertension.

What determines propensity score depends on what we are determining propensity for: comment on a recent analysis of arterial access route in acute myocardial infarction.

J. LeLorier, S. Mansour, B. Potter, 2012, JACC. Cardiovascular interventions.

Long-term survival and functional status in the elderly after cardiac surgery.

J. LeLorier, R. Gagnon, V. Page, 1997, The Canadian journal of cardiology.

Gastrointestinal-Related Healthcare Resource Usage Associated with a Fixed Combination of Diclofenac and Misoprostol versus Other NSAIDs

E. Rahme, S. Kong, L. Joseph, 2012, PharmacoEconomics.

Framework for the cost-effectiveness of secondary prevention strategies in cardiovascular diseases: A Canadian theoretical modelbased analysis

J. Tardif, M. Dubé, D. Mitchell, 2017 .

Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study

J. LeLorier, A. A. Tahami Monfared, B. Bexton, 2006, Current medical research and opinion.

Association between naproxen use and protection against acute myocardial infarction.

E. Rahme, L. Pilote, J. LeLorier, 2002, Archives of internal medicine.

The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.

E. Rahme, M. Maclure, D. Marshall, 2007, Health Policy.

Performance of the high-dimensional propensity score in adjusting for unmeasured confounders

E. Rahme, J. LeLorier, J. Guertin, 2016, European Journal of Clinical Pharmacology.

Head to head comparison of the propensity score and the high-dimensional propensity score matching methods

Jacques LeLorier, E. Rahme, C. Dormuth, 2016, BMC Medical Research Methodology.

Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance

E. Rahme, L. Blais, J. LeLorier, 2003 .

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting

J. LeLorier, R. Manjunath, P. Lefebvre, 2008 .

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.

J. LeLorier, R. Manjunath, M. Duh, 2008, Current medical research and opinion.

The Impact of a Multidisciplinary Information Technology–Supported Program on Blood Pressure Control in Primary Care

Jacques LeLorier, Sylvie Cossette, Jacques Turgeon, 2009, Circulation. Cardiovascular quality and outcomes.

Sex Differences in the Patterns of Systemic Agent use Among Patients With Psoriasis: A Retrospective Cohort Study in Quebec, Canada

E. Rahme, A. Holbrook, M. Brouillette, 2022, Frontiers in Pharmacology.

High-performance liquid chromatography determination of dipotassium clorazepate and its major metabolite nordiazepam in plasma.

J. LeLorier, G. Sirois, P. Colin, 1983, Journal of chromatography.

Does Diabetes Increase the Risk for Fractures After Solid Organ Transplantation? A Nested Case‐Control Study

E. Rahme, J. LeLorier, O. Sheehy, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The missing cause approach to unmeasured confounding in pharmacoepidemiology

M. Abrahamowicz, J. LeLorier, L. Bjerre, 2016, Statistics in medicine.

The gastric antisecretory effects of clofibrate in the rat.

J. LeLorier, L. Tétreault, M. Rheault, 1982, Revue canadienne de biologie experimentale.

Diagnostic accuracy of algorithms to identify hepatitis C status, AIDS status, alcohol consumption and illicit drug use among patients living with HIV in an administrative healthcare database

M. Abrahamowicz, J. LeLorier, Madeleine Durand, 2015, Pharmacoepidemiology and drug safety.

(Arch. Intern. Med., 137:1429-1434)Diet and probucol in lowering cholesterol concentrations

J. LeLorier, J. Davignon, Y. S. Huang, 1977 .

Pain and quality of life assessment after endovascular versus open repair of abdominal aortic aneurysms in patients at low risk.

G. Soulez, M. Giroux, M. Choinière, 2005, Journal of vascular and interventional radiology : JVIR.

Vascular Access-Related Bloodstream Infections in First Nations, Community and Teaching Canadian Dialysis Units, and Other Centre-Level Predictors

E. Rahme, K. Dasgupta, P. Barré, 2009, Nephron Clinical Practice.

Shanghai trial of nifedipine in the elderly

P. Hamet, P. Ghadirian, J. LeLorier, 1996 .

Future MS care: a consensus statement of the MS in the 21st Century Steering Group

Jacques LeLorier, Sven Schippling, D. Centonze, 2012, Journal of Neurology.

Healthcare Utilization after Acute Kidney Injury in the Pediatric Intensive Care Unit.

V. Phan, M. Dorais, J. Lacroix, 2018, Clinical journal of the American Society of Nephrology : CJASN.

Association Between Use of Acid-Suppressive Drugs and Risk of Gastric Cancer

A. Duranceau, H. Tamim, J. LeLorier, 2008, Drug safety.

Use of Continuous Exposure Variables when Examining Dose-Dependent Pharmacological Effects - Application to the Association between Exposure to Higher Statin Doses and the Incidence of Diabetes.

E. Rahme, J. LeLorier, J. Guertin, 2017, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.

Jacques LeLorier, Michael Drummond, Douglas K. Martin, 2009, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?

A. Barkun, E. Rahme, Y. Toubouti, 2007, Arthritis and rheumatism.

Selection of controls in database case-control studies: glucocorticoids and the risk of glaucoma.

J. Boivin, S. Suissa, E. Garbe, 1998, Journal of clinical epidemiology.

Acute otitis media in children: a retrospective analysis of physician prescribing patterns.

J. Collet, C. Quach, J. LeLorier, 2004, British journal of clinical pharmacology.

Active Surveillance in Prostate Cancer How Far Should We Go

J. LeLorier, C. M-H., Aizer Aa, 2016 .

Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

Jason R Guertin, Dominic Mitchell, Farzad Ali, 2015, ClinicoEconomics and outcomes research : CEOR.

Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada.

E. Rahme, Y. Toubouti, J. LeLorier, 2006, The Journal of rheumatology.

Association between nonnaproxen NSAIDs, COX‐2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study

E. Rahme, S. Kong, Y. Toubouti, 2007, Pharmacoepidemiology and drug safety.

Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain—Reply

E. Rahme, L. Pilote, J. LeLorier, 2002 .

Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study

J. Tardif, J. Turgeon, M. Dubé, 2018, Clinical cardiology.

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.

H. Birnbaum, P. Greenberg, J. LeLorier, 2000, Clinical therapeutics.

Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.

S. Lévesque, P. Khairy, M. Talajic, 2013, The Canadian journal of cardiology.

Evaluation of a workplace health program to reduce coronary risk factors

G. Dagenais, L. Makrides, P. Veinot, 2008 .

Patterns of prescription of nonsteroidal antiinflammatory drugs and gastroprotective agents.

J. LeLorier, 1995, The Journal of rheumatology. Supplement.

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin

D. Mitchell, J. LeLorier, J. Guertin, 2016, Molecular Diagnosis & Therapy.

Atrial fibrillation: a real-life observational study in the Québec population.

P. Khairy, A. Matteau, M. Talajic, 2011, The Canadian journal of cardiology.

Statin Initiation: Guideline Concordance and Characteristics of New Users in Quebec, Canada

D. Gaudet, J. Tardif, M. Dubé, 2020, Journal of Population Therapeutics and Clinical Pharmacology.

Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease.

R. Hunt, C. Bombardier, V. Huckell, 2002, The Canadian journal of cardiology.

Clopidogrel and long-term outcomes after drug-eluting stent implantation.

A. Matteau, J. LeLorier, 2007, JAMA.

A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes

M. Dorais, C. Charbonneau, J. LeLorier, 2008 .

Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.

M. Levine, A. Holbrook, J. LeLorier, 2014, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

Pharmacoeconomics and health policy. Current applications and prospects for the future.

H. Birnbaum, P. Greenberg, P. Ouellette, 1999, PharmacoEconomics.

A concurrent cohort study of oral contraceptive users from the VAMP research bank

W. Spitzer, M. Thorogood, S. Suissa, 1993 .

Sex differences in factors associated with switch between systemic agents among individuals with psoriasis: A retrospective cohort study in Quebec, Canada

E. Rahme, A. Holbrook, M. Brouillette, 2021, JAAD international.

Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance.

E. Rahme, L. Blais, J. LeLorier, 2003, Health policy.

Predictors of persistence of use of the novel antidiabetic agent acarbose.

J. LeLorier, V. S. Catalan, J. Couture, 2001, Archives of internal medicine.

Bioavailabllity of lidocaine in normal volunteers and cirrhotic patients

J. LeLorier, P. Huet, D. Marleau, 1978 .